Late-Stage Data Advantage Or Just Late To The Game: Bristol’s Opdivo Approval Sets Off PD-1 Competition

Nivolumab approval for melanoma pits more mature data set against first-to-market advantage as company sets to compete against the first PD-1 immunotherapy to market, Merck’s Keytruda.